Menu
Search
|

Menu

Close
X

Ritter Pharmaceuticals Inc RTTR.OQ (NASDAQ Stock Exchange Capital Market)

0.85 USD
-- (--)
As of Nov 13
chart
Previous Close 0.85
Open --
Volume --
3m Avg Volume 16,268
Today’s High --
Today’s Low --
52 Week High 3.99
52 Week Low 0.80
Shares Outstanding (mil) 5.73
Market Capitalization (mil) 4.88
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-1.979
FY17
-5.313
FY16
-20.001
FY15
-18.520
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
29.57
Price to Sales (TTM)
vs sector
--
15.43
Price to Book (MRQ)
vs sector
0.69
4.06
Price to Cash Flow (TTM)
vs sector
--
21.23
Total Debt to Equity (MRQ)
vs sector
0.00
14.84
LT Debt to Equity (MRQ)
vs sector
0.00
11.13
Return on Investment (TTM)
vs sector
-214.04
12.77
Return on Equity (TTM)
vs sector
-375.26
14.47

EXECUTIVE LEADERSHIP

Ira Ritter
Executive Chairman of the Board, Chief Strategic Officer, Since 2014
Salary: $308,332.00
Bonus: $97,571.00
Andrew Ritter
President, Chief Executive Officer, Founder, Director, Since 2018
Salary: $324,010.00
Bonus: $117,180.00
John Beck
Chief Financial Officer, Since 2018
Salary: --
Bonus: --
Michael Step
Director, Since 2018
Salary: $376,269.00
Bonus: --
Noah Doyle
Independent Director, Since
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1880 Century Park E Ste 1000
LOS ANGELES   CA   90067-1623

Phone: +1310.2031000

Ritter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

SPONSORED STORIES